BNTX - Investor Notice: Robbins LLP Informs Investors of Class Action Filed Against BioNTech SE (BNTX) | Benzinga

SAN DIEGO, Jan. 16, 2024 (GLOBE NEWSWIRE) -- Robbins LLP informs investors that a shareholder filed a class action on behalf of all persons and entities that purchased or otherwise acquired BioNTech SE (NASDAQ:BNTX) between March 30, 2022 and October 13, 2023. BioNTech is a biotechnology company that develops and commercializes immunotherapies for cancer and other infectious diseases. The Company has developed and continues to develop, among other products and product candidates, Comirnaty, a COVID-19 vaccine, in collaboration with Pfizer Inc.

For more information, submit a form, email Aaron Dumas, Jr., or give us a call at (800) 350-6003.

What is this Case About: BioNTech SE (BNTX) Allegedly Misled Investors Regarding its Business Prospects

According to the complaint, during the class period, defendants failed to disclose that: (i) BioNTech overstated demand for Comirnaty and/or its commercial prospects; (ii) the Company and/or Pfizer had accumulated excess inventory of raw materials for Comirnaty, as well as COVID-19 vaccine doses adapted to other, non-XBB.1.5 variants that were produced at risk; and (iii) ...

BNTX)>Full story available on Benzinga.com